Clinical Trial

REDUCER Trial (TXA in Urethroplasty)

Study acronym: REDUCER
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study will test whether tranexamic acid (TXA), a medication used to reduce bleeding, can decrease blood loss in patients having urethroplasty. Participants will be randomly assigned to receive either a single intravenous dose of TXA at the start of anesthesia or standard care without TXA. Researchers will compare hemoglobin change after surgery as well as estimated blood loss and complications.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-12-31 -> 2027-12-31 2026-08-14
minor Completion pushed: 2027-03-30 -> 2028-03-30 2026-08-14
Trial Details
NCT Number NCT07501884
Lead Sponsor Amjad Alwaal, MD, MSc, FRCSC, FACS
Conditions Urethral Stricture, Urethral Diseases
Enrollment 40 participants
Start Date 2026-09-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-13